All In Biotech

Drug Trial Radar · NCT02886702

A Study Comparing Tazarotene Cream 0.05% to TAZORAC® (Tazarotene) Cream 0.05% and Both to a Placebo Control in the Treatment of Plaque Psoriasis

A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing Tazarotene Cream 0.05% to TAZORAC® (Tazarotene) Cream 0.05% and Both Active Treatments to a Vehicle Control in the Treatment of Stable Plaque Psoriasis

Last checked: Nov 19, 2026Latest source record: Aug 29, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 855 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

855

Actual

Start

Sep 19, 2016

Primary completion

Aug 2, 2017

Study completion Aug 2, 2017

Sponsor

Lead sponsor
Fougera Pharmaceuticals Inc.Industry
Sponsor type
Industry
First posted
Sep 1, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing Tazarotene Cream 0.05% to TAZORAC® (tazarotene) Cream 0.05% and Both Active Treatments to a Vehicle Control in the Treatment of Stable Plaque Psoriasis

Conditions

  • Plaque Psoriasis

Interventions

  • Tazarotene Cream 0.05%Drug

    Tazarotene Cream 0.05% to cover only the lesions with a thin film.

  • TAZORAC® (tazarotene) Cream 0.05%Drug

    TAZORAC® (tazarotene) Cream 0.05% to cover only the lesions with a thin film.

  • PlaceboDrug

    Placebo (vehicle of the test product) to cover only the lesions with a thin film.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Treatment Success Assessed by IGATime frame: Week 12

Locations

30 sites in 1 country. Site status is shown where the registry gives one.

  • Fougera Investigational Site

    Phoenix, Arizona

  • Fougera Investigational Site

    Hot Springs, Arkansas

  • Fougera Investigational Site

    Anaheim, California

  • Fougera Investigational Site

    North Hollywood, California

  • Fougera Investigational Site

    San Diego, California

  • Fougera Investigational Site

    San Ramon, California

  • Fougera Investigational Site

    Brandon, Florida

  • Fougera Investigational Site

    Coral Gables, Florida

  • Fougera Investigational Site

    Hialeah, Florida

  • Fougera Investigational Site

    Miami, Florida

  • Fougera Investigational Site

    Miami, Florida

  • Fougera Investigational Site

    Miami, Florida

  • Fougera Investigational Site

    Miami Gardens, Florida

  • Fougera Investigational Site

    Miramar, Florida

  • Fougera Investigational Site

    Sweetwater, Florida

  • Fougera Investigational Site

    Tampa, Florida

  • Fougera Investigational Site

    West Palm Beach, Florida

  • Fougera Investigational Site

    Macon, Georgia

  • Fougera Investigational Site

    Arlington Heights, Illinois

  • Fougera Investigational Site

    New Albany, Indiana

  • Fougera Investigational Site

    Plainfield, Indiana

  • Fougera Investigational Site

    Louisville, Kentucky

  • Fougera Investigational Site

    Lake Charles, Louisiana

  • Fougera Investigational Site

    Saint Joseph, Missouri

  • Fougera Investigational Site

    Henderson, Nevada

  • Fougera Investigational Site

    High Point, North Carolina

  • Fougera Investigational Site

    Salem, Oregon

  • Fougera Investigational Site

    Hazleton, Pennsylvania

  • Fougera Investigational Site

    Upper Saint Clair, Pennsylvania

  • Fougera Investigational Site

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.